切换至 "中华医学电子期刊资源库"
高级检索
中华肾病研究电子杂志

中华肾病研究电子杂志 ›› 2018, Vol. 07 ›› Issue (03) : 122 -125. doi: 10.3877/cma.j.issn.2095-3216.2018.03.006

所属专题： 文献；

论著

氨甲酰化促红细胞生成素对慢性肾衰竭合并急性肾损伤大鼠肾脏的保护作用
梅艳1, 洪权1, 马倩1, 张杰1, 谢院生1, 蔡广研1, 陈香美1,†()   
  1. 1. 100853　北京，解放军总医院肾脏病科、解放军肾脏病研究所、肾脏疾病国家重点实验室、国家慢性肾病临床医学研究中心
  • 收稿日期:2018-01-17 出版日期:2018-06-28
  • 通信作者: 陈香美
  • 基金资助:
    国家自然科学基金(81470949，81670671，82473531); 国家科技支撑计划(2015BAI12B06)

Renal protective effects of carbamylated erythropoietin in chronic renal failure rats complicated with acute kidney injury

Yan Mei1, Quan Hong1, Qian Ma1, Jie Zhang1, Yuansheng Xie1, Guangyan Cai1, Xiangmei Chen1,†()   

  1. 1. Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing 100853, China
  • Received:2018-01-17 Published:2018-06-28
  • Corresponding author: Xiangmei Chen
  • About author:
    Corresponding author: Chen Xiangmei, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

梅艳, 洪权, 马倩, 张杰, 谢院生, 蔡广研, 陈香美. 氨甲酰化促红细胞生成素对慢性肾衰竭合并急性肾损伤大鼠肾脏的保护作用[J]. 中华肾病研究电子杂志, 2018, 07(03): 122-125.

Yan Mei, Quan Hong, Qian Ma, Jie Zhang, Yuansheng Xie, Guangyan Cai, Xiangmei Chen. Renal protective effects of carbamylated erythropoietin in chronic renal failure rats complicated with acute kidney injury[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2018, 07(03): 122-125.

目的

观察氨甲酰化促红细胞生成素(carbamylated erythropoietin, CEPO)对慢性肾脏病(CKD)合并急性肾损伤(AKI)大鼠模型的肾脏保护作用。

方法

取健康雄性SD大鼠(450±20 g)39只，随机分为3组，首先制作5/6肾切除大鼠慢性肾衰模型，10 d后确认大鼠慢性肾衰竭模型造模成功。在该慢性肾衰竭模型大鼠双后肢肌肉按照8 ml/kg的剂量注射50%甘油制作合并急性肾损伤模型。第11，12，13天向各组注射：生理盐水(NS)组：腹腔注射生理盐水；促红细胞生成素(EPO)组：按照5 000 U/kg的剂量向大鼠腹腔内注射EPO；CEPO组：按照5 000 U/kg的剂量进行腹腔注射CEPO。在第1，5，10，11，13，17天对大鼠的体重、血压进行检测，同时尾静脉采血对红细胞比容、血肌酐、尿素氮进行检测，留取肾组织进行病理学PAS检测。用SPSS 19.0统计软件对实验数据进行统计学处理，P<0.05被认为差异有统计学意义。

结果

与生理盐水注射组比较，CEPO组和EPO组可缓解大鼠体重的减轻幅度(F＝8.19，F＝6.84, P<0.05)，可保护大鼠肾功能，降低大鼠血肌酐(F＝5.12, F＝13.72, P<0.05)和血尿素(F＝4.63，F＝12.78, P<0.05)的水平，减轻肾脏小管病理损伤(F＝9.14, F＝12.73, P<0.05)，并且CEPO组能显示出更明显的作用(P<0.05)，CEPO相对于EPO能够缓解升高红细胞比容的副作用(F＝8.27, P＝0.019)。

结论

CEPO对CKD合并AKI模型大鼠能起到明显的肾脏保护作用，并且相对于EPO治疗能降低引起红细胞比容升高的副作用。

关键词: 慢性肾脏疾病, 急性肾损伤, 氨甲酰化促红细胞生成素
Objective

To observe the renal protective effects of carbamylated erythropoietin (CEPO) in rats with chronic kidney disease (CKD) complicated with acute kidney injury (AKI).

Methods

Thirty-nine healthy male SD rats (450±20 g) were randomly divided into three groups. Firstly, the model of chronic renal failure was made by 5/6 nephrectomy in rats, and was confirmed 10 days later. Afterwards, the model of complicated AKI was made by injection in the hind limb muscle with 50% glycerol at a dose of 8 ml/kg. On the 11th, 12th, and 13th day, each group was treated with intraperitoneal injection of normal saline (NS group), erythropoietin at a dose of 5 000 U/kg (EPO group), and CEPO at a dose of 5 000 U/kg (CEPO group). On the 1st, 5th, 10th, 11th, 13th, and 17th day, the body weight and blood pressure of the rats were detected. At the same time, blood from the tail vein was used to detect hematocrit, serum creatinine, and urea nitrogen, and the renal tissues were taken for pathological periodic acid-Schiff (PAS) staining. The experimental data were processed with SPSS 19.0 statistical software. P<0.05 was considered statistically significant.

Results

Compared with the NS group, the CEPO group and the EPO group relieved the weight loss of rats (F=8.19, F=6.84, P<0.05), reduced the levels of Scr (F=5.12, F=13.72, P<0.05)and BUN (F=4.63, F=12.78, P<0.05), and reduced the renal tubular pathological damage (F=9.14, F=12.73, P<0.05). The CEPO group′s effects were more obvious than those of the EPO group (P<0.05). And CEPO relieved the increase of hematocrit, the side effect of EPO(F=8.27, P=0.019).

Conclusions

CEPO showed significant renal protective effects in the CKD rat model complicated with AKI. The CEPO treatment could also reduce the increased level of hematocrit.

Key words: Chronic kidney disease, Acute kidney injury, Carbamylated erythropoietin
图1 A：术后不同时间各组大鼠血肌酐水平。与NS组比较，aP<0.05；与EPO组比较，bP<0.05；NS：生理盐水组；EPO：EPO注射组；CEPO：CEPO注射组；每组n≥6; B：术后不同时间各组大鼠血尿素氮水平。与NS组比较，aP<0.05；与EPO组比较，bP<0.05；NS：生理盐水组；EPO：EPO注射组；CEPO：CEPO注射组；每组n≥6
图2 术后不同时间各组大鼠红细胞比容水平
图3 术后各组大鼠肾脏病理表现(PAS×400)
[1]
Zuk A, Bonventre JV. Acute kidney injury: can remote ischaemic preconditioning prevent AKI? [J]. Nat Rev Nephrol, 2015, 11(9): 512-513.
[2]
Doi K, Rabb H. Impact of acute kidney injury on distant organ function: recent findings and potential therapeutic targets [J]. Kidney Int, 2016, 89(3): 555-564.
[3]
Collister D, Komenda P, Hiebert B, et al. The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis [J]. Ann Intern Med, 2016, 164(7): 472-478.
[4]
Chen J, Yang Z, Zhang X. Carbamylated erythropoietin: a prospective drug candidate for neuroprotection [J]. Biochem Insights, 2015, 8(Suppl 1): 25-29.
[5]
Deak AT, Troppan K, Rosenkranz AR. Anemia management in cancer patients with chronic kidney disease [J]. Eur J Intern Med, 2016, 36: 13-19.
[6]
Brines M, Cerami A. Discovering erythropoietin′s extra-hematopoietic functions: biology and clinical promise [J]. Kidney Int, 2006, 70(2): 246-250.
[7]
Ocmen E, Derbent A, Micilli SC, et al. Erythropoietin diminishes isoflurane-induced apoptosis in rat frontal cortex [J]. Paediatr Anaesth, 2016, 26(4): 444-451.
[8]
Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic [J]. Science, 2004, 305(5681): 239-242.
[9]
Geng X, Wang Y, Hong Q, et al. Differences in gene expression profiles and signaling pathways in rhabdomyolysis-induced acute kidney injury [J]. Int J Clin Exp Pathol, 2015, 8(11): 14087-14098.
[10]
Geng XD, Zheng W, Wu CM, et al. Embryonic stem cells-loaded gelatin microcryogels slow progression of chronic kidney disease [J]. Chin Med J (Engl), 2016, 129(4): 392-398.
[1] 张秋彬, 张楠, 林清婷, 徐军, 朱华栋, 姜辉. 急性胰腺炎合并急性肾损伤患者的预后评估[J]. 中华危重症医学杂志(电子版), 2023, 16(05): 382-389.
[2] 韩圣瑾, 周正武, 翁云龙, 黄鑫. 碳酸氢钠林格液联合连续性肾脏替代疗法对创伤合并急性肾损伤患者炎症水平及肾功能的影响[J]. 中华危重症医学杂志(电子版), 2023, 16(05): 376-381.
[3] 莫小乔, 胡喆莹, 廖冬花, 谢天. 脓毒症继发急性肾损伤患者死亡风险预测模型构建及评估[J]. 中华危重症医学杂志(电子版), 2023, 16(03): 198-206.
[4] 吴庆华, 冒勇, 闫效坤. AECOPD并发AKI的危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 529-531.
[5] 李青霖, 宋仁杰, 周飞虎. 一种重型劳力性热射病相关急性肾损伤小鼠模型的建立与探讨[J]. 中华肾病研究电子杂志, 2023, 12(05): 265-270.
[6] 任加发, 邬步云, 邢昌赢, 毛慧娟. 2022年急性肾损伤领域基础与临床研究进展[J]. 中华肾病研究电子杂志, 2023, 12(05): 276-281.
[7] 李金璞, 饶向荣. 抗病毒药物和急性肾损伤[J]. 中华肾病研究电子杂志, 2023, 12(05): 287-290.
[8] 宋艳琪, 任雪景, 王文娟, 韩秋霞, 续玥, 庄凯婷, 肖拓, 蔡广研. 间充质干细胞对顺铂诱导的小鼠急性肾损伤中细胞铁死亡的作用[J]. 中华肾病研究电子杂志, 2023, 12(04): 187-193.
[9] 程庆砾. 新冠病毒感染与肾脏[J]. 中华肾病研究电子杂志, 2023, 12(04): 240-240.
[10] 苗软昕, 乔晞. Toll样受体在脓毒症性急性肾损伤中的作用[J]. 中华肾病研究电子杂志, 2023, 12(04): 210-214.
[11] 李娜, 朱国贞. 肠道菌群及其代谢产物在急性肾损伤中的作用研究进展[J]. 中华肾病研究电子杂志, 2023, 12(04): 215-219.
[12] 于天宇, 杨悦, 陆海涛, 田志永, 李文歌. 高龄急性肾损伤患者连续性肾脏替代治疗的预后及影响因素[J]. 中华肾病研究电子杂志, 2023, 12(03): 134-138.
[13] 任国华, 杜晓晓, 洪善玲, 邵帅. 妊娠期高血压并发急性肾损伤患者血清白细胞介素-22、硫化氢及护骨素水平的变化与意义[J]. 中华肾病研究电子杂志, 2023, 12(03): 150-155.
[14] 王蕤, 乔晞. 重症监护室发生急性肾损伤的危险因素[J]. 中华肾病研究电子杂志, 2023, 12(02): 93-96.
[15] 易成, 韦伟, 赵宇亮. 急性肾脏病的概念沿革[J]. 中华临床医师杂志(电子版), 2023, 17(08): 906-910.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号